Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.36 |
| ▸ | GRM5 | P41594 | 3/20 | 0.33 |
| ▸ | BACE1 | P56817 | 3/20 | 0.32 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.31 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17761607 | 0.78 | UHRF1 (0.48) | CYP1A1CYP1A2CYP1B1GRM5FFAR1 | |
| SCHEMBL17039214 | 0.77 | LOXL2 (0.35) | GRM5BACE1MAPT | |
| SCHEMBL29994323 | 0.77 | LOXL2 (0.35) | GRM5BACE1MAPT | |
| SCHEMBL9947880 | 0.77 | FFAR1 (0.46) | CYP1A1CYP1A2CYP1B1GRM5FFAR1 | |
| SCHEMBL9948329 | 0.77 | KDM4E (0.38) | CYP1A2BACE1 | |
| SCHEMBL931687 | 0.77 | CYP1A1 (0.35) | CYP1A1CYP1A2CYP1B1BACE1FFAR1 | |
| SCHEMBL30477794 | 0.77 | KDM4E (0.38) | CYP1A2BACE1 | |
| SCHEMBL23704304 | 0.74 | CCR1 (0.53) | CYP1A1CYP1A2CYP1B1GRM5 | |
| SCHEMBL10038829 | 0.74 | NOS3 (0.50) | CYP1A2BACE1MAP3K14 | |
| SCHEMBL931599 | 0.74 | CYP1A1 (0.33) | CYP1A1CYP1A2CYP1B1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1368317-B1 | TRYPTASE INHIBITORS | ALTANA PHARMA AG (DE) | 2006-12-27 | — | — | EP | disclosed |
| US-7060716-B2 | Compound containing two triple bonds | ALTANA PHARMA AG (DE) | 2006-06-13 | — | — | US | disclosed |
| US-20040067943-A1 | Tryptase inhibitors | ALTANA PHARMA AG (DE) | 2004-04-08 | — | — | US | disclosed |
| EP-1368317-A1 | TRYPTASE INHIBITORS | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002066430-A1 | TRYPTASE INHIBITORS | ALTANA PHARMA AG (DE) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067943-A1 | Tryptase inhibitors | TPSB2, TPSAB1, TPSG1 | CYP1A1 955/4885CYP1A2 519/4885CYP1B1 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.